- Home
- CGO vs IXHL Comparison
CGO vs IXHL Comparison
Compare CGO & IXHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | CGO | IXHL |
|---|---|---|
| Founded | 2004 | 2001 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Investment Managers | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 112.9M | 97.6M |
| IPO Year | N/A | 2024 |
Fundamental Metrics
Financial Performance| Metric | CGO | IXHL |
|---|---|---|
| Price | $11.39 | $5.33 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 33.8K | ★ 4.5M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 9.25% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $12,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.71 | $0.11 |
| 52 Week High | $12.79 | $5.17 |
Technical Indicators
Market Signals| Indicator | CGO | IXHL |
|---|---|---|
| Relative Strength Index (RSI) | 35.18 | 87.69 |
| Support Level | $11.40 | $0.31 |
| Resistance Level | $11.85 | $5.17 |
| Average True Range (ATR) | 0.17 | 0.33 |
| MACD | -0.14 | 0.36 |
| Stochastic Oscillator | 28.29 | 88.86 |
Price Performance
Historical ComparisonAbout CGO Calamos Global Total Return Fund
Calamos Global Total Return Fund is a closed-end management investment company. The fund's investment objective is to provide total return through a combination of capital appreciation and current income. The fund invests in equities, convertible securities, and high-yield corporate bonds.
About IXHL Incannex Healthcare Inc.
Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.